The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | An insight into how novel agents are influencing survival outcomes in patients with MF
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on survival outcomes in patients with myelofibrosis (MF) and how novel agents, such as JAK inhibitors, have improved patient quality of life and symptoms. Dr Masarova also explains the challenges with directly assessing survival outcomes and the need to obtain more detailed data from clinical trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
